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Abstract
Objectives
Disutility allows to identify how much population values intervention-related harms contribut-
ing to knowledge on the benefits/harms ratio of cancer screening programs. This systematic
review evaluates disutility related to cancer screening applying a utility theory framework.
Methods
Using a predefined protocol, Embase, Medline Ovid, Web of Science, Cochrane, Google
scholar and supplementary sources were systematically searched. The framework grouped
disutilities associated with breast, cervical, lung, colorectal, and prostate cancer screening
programs into the screening, diagnostic work up, and treatment phases. We assessed the
quality of included studies according to the relevance to target population, risk of bias,
appropriateness of measure and the time frame.
Results
Out of 2840 hits, we included 38 studies, of which 27 measured (and others estimated) dis-
utilities. Around 70% of studies had medium to high-level quality. Measured disutilities and
Quality Adjusted Life Years loss were 0–0.03 and 0–0.0013 respectively in screening
phases. Both disutilities and Quality Adjusted Life Years loss had similar ranges in diagnos-
tic work up (0–0.26), and treatment (0.09–0.27) phases. We found no measured disutilities
available for lung cancer screening and—little evidence for disutilities in treatment phase.
Almost 40% of the estimated disutility values were above the range of measured ones.
Conclusions
Cancer screening programs led to low disutities related to screening phase, and low to mod-
erate disutilities related to diagnostic work up and treatment phases. These disutility values
varied by the measurement instrument applied, and were higher in studies with lower qual-
ity. The estimated disutility values comparing to the measured ones tended to overestimate
the harms.
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Introduction
Cancer is one of the most wide-spread chronic diseases with an estimated 18.1 million of new
cases in 2018 leading to 9.6 million deaths worldwide.[1] Among all malignancies, the diseases
with the highest five-year prevalence in 2017 were breast (19%), prostate (12%), colorectal
(11%), lung (5.8%), and cervical (4.8%) cancers. [2]
Cancer screening programs can help to detect the disease before symptoms appear. Empiri-
cal studies show the benefits of cancer screening in decreasing the mortality of the most preva-
lent cancers. For example, the US Preventive Services Task Force meta-analyses showed 15%-
20% reduction in breast cancer mortality with mammography screening and 20–60% reduc-
tion in cervical cancer mortality with cytology-based screening. [3,4] The International Agency
for Research on Cancer reported 18–31% reduction of colorectal cancer mortality due to sig-
moidoscopy screening, [5] while the National Cancer Institute reported a 20% reduction in
lung cancer mortality among smokers with low dose computed tomography screening.[6]
While some of the cancer screening programs (for breast, cervical, and colon cancers) are
widely implemented, there are increasing concerns on possible harms of screening.[5,7] These
harms mainly include anxiety, procedural risks, false positive diagnosis, and overdiagnosis (diag-
nosing cancers that would never have caused any symptoms).[8–11] Prevention strategies must be
first of all safe, and so governmental bodies pay high attention to assessments of possible screen-
ing-related harms which could lead to retreat or delay of cancer screening programs. [12–14]
Harms can be either assessed from clinical endpoints or represented by patients’ values for
the outcomes. Preferences of population for screening programs may be expressed in utility
values, while screening-related harms (or loss in health-related quality of life) illustrated in dis-
utility values. [15] Methods of deriving health state utility values (HSUVs) include direct and
indirect methods. The examples of direct approaches include Time Trade Off (TTO), Standard
Gamble (SG), Visual Analog Scale (VAS), and Discrete Choice Experiment (DCE). Among the
indirect instruments are EuroQol 5 Dimensions (EQ-5D), Short Form 6 Dimension (SF-6D),
Rand-36, and Health Utilities Index (HUI). [16] These methods are rooted in utility theories
that reflect the consumer satisfaction over the choices. [17,18]
Utilities as measures of patient preferences are widely considered in health decision mak-
ing, as a component of quality adjusted life years (QALYs) in cost-effectiveness analysis. The
QALYs are calculated as HSUVs multiplied by time spent in certain health state (called time
frame). Theoretically the disutility value equals to “1-utility”, so the larger disutility related to
screening then the lower total utility for the screened population. QALYs losses (disutility
value multiplied by time frame) express the general harms of the screening program.
Knowledge on screening-related disutilities is a crucial component in understanding of
benefits/harms ratio of cancer screenings. Meanwhile, no systematic review summarized this
evidence so far. [19–21] Our study aims to fill in this gap by identifying typologies of disutili-
ties and further evaluating the reliability and variability in disutility values.
Methods
Search and selection
We systematically searched Embase, Medline Ovid, Web of Science, Cochrane, and Google
scholar from their commencements till April 2018. The search syntax (S1 File) was developed
with an input from a qualified librarian. We also searched non-systematically the other supple-
mentary sources (S2 File) and references of the included studies.
One researcher (LL) screened and included all abstracts focused on lung, breast, colorectal,
cervical or prostate cancers reporting the results of studies of various designs (models,
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randomized controlled trials, cohort or case-controlled studies, and systematic reviews). We
excluded studies that were: (1) related to other diseases; (2) reporting clinical utility/practice
(for example, screening methodology, compliance, clinical diagnosis or treatment); or (3) not
full-text papers (meeting proceedings, posters or commentaries). All full texts of included
abstracts were double screened (by LL and OM) excluding studies that did not report disutility
values or reported disutility values cited from another source (in this case the original source
was used). If the author used disutility from the literature but also applied certain assumptions
for the value, and therefore its value differs from the cited value, then it was included as esti-
mated value.
All the relevant information from the included studies was extracted by one author (LL)
using a data extraction form, and verified by the second author (OM).
Theoretical framework of the review
Referring to the American College of Physicians’ value framework for cancer screening,[12]
we grouped the reported disutility into three typologies (Fig 1).
a. Screening phase: the disutility is normally derived from the primary screening test because
of the discomfort during the procedure and have a short-term effect, generally from a few
days and up to 3 weeks.
b. Diagnostic work up phase: the disutility at this stage is not only caused by physical effects
(such as discomfort or complication from follow up or repeated tests’ procedure), but also
by psychological effects (such as anxiety and emotional distress about unfavorable or inde-
terminate result). The time frame of this stage ranges from a few weeks to a few months.
Disunities in this phase were divided into three groups:
Fig 1. Disutility typologies.Notes: HPV = Human papillomavirus; PSA = prostate specific antigen; MRI =Magnetic resonance
imaging; DRE = digital rectal examination; TRUS = trans-rectal ultrasound; LDCT = Low dose Computed Tomography;
FNA = Fine needle aspiration; FOBT = fecal occult blood testing; FIT = fecal immunofluorenscence testing.
https://doi.org/10.1371/journal.pone.0220148.g001
Disutility in cancer screening programs
PLOS ONE | https://doi.org/10.1371/journal.pone.0220148 July 24, 2019 3 / 17
Ⴗ. False positive results
Ⴗ. Procedure-wise
Ⴗ. Abnormal results.
c. Treatment phase: The disutility in this phase is related to overtreatment of the screening
detected (or overdiagnosed) cancer. The time frame generally ranges from several months
to years.
Quality appraisal
We developed the quality appraisal criteria based on Ara et al. (2017) [22] and Papaioannou et al
(2013) [23] (Table 1). For each of the criteria the studies were scored as ‘good’ (score 2), ‘fair’
(score 1) or ‘poor’ (score 0). The studies with an overall score of�7, 5–6, 3–4,< 3 were rated as
high, medium, low, very low quality respectively. Quality of the included studies was assessed
independently by two reviewers (LL, OM) with disagreements being solved by consensus.
Data synthesis
We reported the disutility values by typology and cancer type respectively. The study aimed to
combine the disutility values in meta-analysis under conditions of sufficient number of values
Table 1. Checklist for quality appraisal.
Criteria Description
Relevance to the population’s preference
Respondent selection and
recruitment
Does this result in a population comparable to that being evaluated?
Inclusion/exclusion criteria Do the criteria exclude any individuals? (for example, the elderly>80-year-old are
often not included in studies)
Relevance of location Are the population recruited from multiple locations?
Quality assessment—Risk of bias
Sample size Is the sample size appropriate in reflection population’s preference?
Response rates to the
measure used
Are the response rates reported? If so, are the rates likely to be a threat to the validity
of the estimated health state utility values?
Loss to follow-up How large is the loss to follow-up and are the reasons for it given? Are these likely to
threaten the validity of the estimates?
Missing data Are missing values well-reported and addressed? What are the levels of missing data
and how are they dealt with? Could this threaten the validity of the estimates?
Appropriateness of measure of disutility values
Appropriate use of
instrument
For direct methods (DCE, TTO, SG, VAS): Is the method used appropriately? If
anchors are used describing the perfect and worse health (for example anchored at 1
as equivalent to full health and 0 as equivalent to dead)?
For indirect method (EQ-5D, SF-6D, SF-36, HUI): Are the adequate details of the
method provided (for example, the details given on the version used, the social tariff
applied, etc.)?
Time frame Is the time frame specified? If so, is it sufficient or reliable to account for the
magnitude of harm from screening (when relevant)? Time frame preferences:
Measurement> guideline recommendation or assumption with justification
(example, referring to a local clinical practice, or using the time frame from literature
reviews)> assumption without justifications or no time frame reported (this
criterion was considered as not applicable for DCE studies)
Notes: DCE = Discrete Choice Experiment; TTO = Time Trade Off; SG = Standard Gamble; VAS = Visual Analog
Scale; EQ-5D = EuroQol 5 Dimensions; SF-6D = Short Form 6 Dimension; SF-36 = Short From 36; HUI = Health
Utilities Index
https://doi.org/10.1371/journal.pone.0220148.t001
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(at least ten studies to each covariate [22]) and manageable heterogeneity in methods and out-
comes. Considering that these conditions could not be reached, the qualitative synthesis was
applied. We summarized mean and confidence interval disutility values by typology and can-
cer types; for studies of high and medium quality, we calculated non-reported confidence
intervals when standard deviation was available.
Results
Studies selection and overview
Out of 2840 abstracts identified by databases search and from the other sources, 23 studies met
the eligibility criteria set by this review. Through checking the reference list of the articles,
another 15 studies were included, resulting to 38 papers included in total (Fig 2). The level of
agreement between two reviewers was high (kappa coefficient = 0.99).
A summary of characteristics of the included studies is provided in the Table 2. About 30%
of the studies reported estimated disutility values, while remaining 27 studies evaluated disuti-
lites by direct or indirect instruments. The data extraction form reporting key characteristics
of individual studies is presented in the S1 and S2 Tables.
Around 70% of studies which measured disutility values were rated as medium or high level
of quality (S3 Table). The studies were ranked lower on risk of bias and time frame than the
other quality criteria (Fig 3).
Result on measured disutility
Disutility in screening phase. Eight studies reported disutility related to cervical, breast
and prostate cancer screenings (Fig 4). The disutility associated with cervical cancer screening
Fig 2. PRISMA flow chart of study selection process.
https://doi.org/10.1371/journal.pone.0220148.g002
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ranged 0–0.02 [24,25], and QALY lost 0–0.0006 with 1 to 2 week timeframe. Disutilities related
to breast cancer screening measured with VAS varied–considerably (0.006–0.2).[26–28] Dis-
utility related to prostate cancer screening ranged 0–0.03 and calculated maximum QALYs
loss around 0.0013, with most studies concluding on no disutility from screening attendance.
[29–31] In a nutshell, taken the evidence from medium to high quality studies, the disutility
values due to primary screening attendance were around 0–0.03, and the corresponding
QALYs loss around 0–0.0013.
Disutility in diagnostic work up phase. False positive. Five studies assessed disutility of
false positive result in breast cancer screening [27, 28, 32–34] (Fig 5) in the range of 0–0.26.
Taken into account of the reported time frames (near 12 months), the calculated QALYs loss
were around 0–0.26. Gyrd-Hansen et al (2001) used the DCE method to investigate prefer-
ences to cancer screening programs; the authors concluded that false positive diagnosis has no
impact on utility values for colorectal cancer screening while marginal disutility was confirmed
Table 2. Overview of the included studies (n = 38).
Study Design
Modeling study N = 15
Randomized controlled trial N = 5
Observational study N = 18
Cancer Type
Colorectal cancer N = 6
Cervical cancer N = 17
Breast cancer N = 10
Lung cancer N = 2
Prostate cancer N = 4
Disutility Typology
Screening phase N = 15
Diagnostic work up phase N = 34
Treatment phase N = 3
Instruments used for measurement
Estimation N = 11
Direct method N = 21
TTO N = 4
SG N = 5
VAS / RS N = 9
DCE N = 3
Indirect method N = 15
EQ-5D N = 8
SF-6D N = 3
RAND / SF-36 N = 3
HUI N = 1
Respondent
Average-risk population N = 22
High-risk population N = 2
Healthcare professional/expert N = 4
Time frame
Measurement N = 10
Guideline N = 4
Assumption N = 19
https://doi.org/10.1371/journal.pone.0220148.t002
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due to false positive result in breast cancer screening. [35] In summary, evidence from above
studies showed that the false positive’s disutility values and calculated QALYs loss were in the
range of 0–0.26.
Procedure-wise disutilities. Eleven studies reported the measured disutility values due to
screening procedures for breast, prostate and cervical cancers (Fig 6).
Three studies on breast cancer reported procedure-wise disutilities in the range 0–0.45. [26,
28, 36] No disurilitues found for prostate cancer because of screening procedure. [29, 31] For
cervical cancer, one study tested the procedure-wise disutility related to the repeated pap
smear and colposcopy referral; the disutility values ranged 0–0.03 and the calculated QALYs
Fig 3. Overview of quality appraisal result per individual criteria.
https://doi.org/10.1371/journal.pone.0220148.g003
Fig 4. Disutility values in screening phase.Notes:1) Green color = high quality; Yellow color = medium quality; Grey
color = low quality 2) with � values from experts; without � form general population.
https://doi.org/10.1371/journal.pone.0220148.g004
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loss 0–0.0375. [24] Another five studies investigated the differences in disutility of aggressive
versus conservation protocols for patients with abnormal primary cervical cancer screening
results. [37–41] The conclusions were contradictory whether early colposcopy leads to loss
[38, 39] or gain in utilities.[40] Two studies concluded on disutilities of either immediate
human papilloma virus (HPV) test [37] or immediate treatment and cytological surveillance
versus conservative protocols.[41] Two DCE studies in colorectal cancer screening demon-
strated the disutility of unnecessary colonoscopy and non-accurate or low-sensitivity tests
from general population perspectives, [42, 43] while Marshell et al (2009) found no disutility
of related to colonoscopy usage from physician’s preferences.[43] In general, leveraging the
evidence from medium to high quality studies, the procedure wise disutility were 0–0.03, and
the overall QALYs losses were in the range of 0–0.0375.
Abnormal result related disutility. Seven studies reported substantial variability in disutil-
ity values (the lowest of 0.004 for HPV positive and the highest of 0.4 for cervical intraepithelial
neoplasia [CIN] II-III) and time frames (from 3 to 18 months) because of abnormal results.
(Fig 7) [25, 44–49]
Disutility in treatment phase. The only study reporting disutility in treatment phase, by
Cantor S.B. et al (2008) investigated the couples’ preference for prostate cancer screening out-
comes. Disutility values of 0.09–0.27 were reported because of possible side effects (such as
impotence, urinary incontinence, and injury) from the screening and consequent treatments.
[50]
Summary on measured disutilities by cancer types. Most included studies were on cervi-
cal and breast cancers, while no single study reported the disutility of lung cancer screening.
Similarly, only one study assessed disutility related to treatment phase—overtreatment of pros-
tate cancer (Table 3).
Disutility values by studies’ quality and instrument used. Disutility values varied by
quality of the studies, with values from high-quality studies being generally lower than from
medium and low quality studies (Figs 4–6). At the same time, elicitated disutility values from
indirect method were lower than those values from direct methods in screening-phase, false
positive and procedure-wised disutility (Figs 4–6).
Fig 5. Disutility values for false positive in diagnostic work up phase.Notes: 1) Green color = high quality; Yellow
color = medium quality; Grey color = low quality 2) with � values from experts; without � form general population.
https://doi.org/10.1371/journal.pone.0220148.g005
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Result on estimated disutility. Out of eleven studies that reported the estimated disutility
values, almost 40% assumed values outside of the measured range (Table 4).
Discussion
Our systematic review identified screening, diagnostic work up and treatment phases as three
typologies of disutilities in cancer screening programs. Among these typologies the diagnostic
work-up phase and treatment phases are potentially more important taking into account the
impact on quality of life in terms of a degree of perceived screening–related harms and its time
frame. Considering the analyzed literature on cervical, breast, and prostate cancer, we assume
a low level of harms (less than 0.03 resulting to 0–0.0013 QALY loss) related to disutility from
primary screening and low to moderate level of harms (0–0.26 range for both disutility and
QALY loss) related to diagnostic work up from population perspective. Although women with
false positive diagnosis considered the risk of having it as acceptable,[62] disutilities and
QALYs loss related to false positive rate should not be ignored because of its commonality in
clinical practice (for example, 1–11% in screening mammography [63–65]). Although this
review identified only one study reporting disutility for treatment phase (0.09–0.27), taken
into account the longer timeframe for disutilities related to overdiagnosis, we assume a moder-
ate level of harms perceived in treatment phase.
Fig 6. Procedure-wise disutility values in diagnostic work up phase.Notes: 1) Green color = high quality; Yellow
color = medium quality; Grey color = low quality 2) with � values from experts; without � form general population 3) Different
protocol: Conservative process includes observation, surveillance, follow-up with pap smear tests, aggressive process includes
early colposcopy, immediate HPV tests.
https://doi.org/10.1371/journal.pone.0220148.g006
Disutility in cancer screening programs
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Our review identified the studies both measuring and estimating disutilities related to can-
cer screening. An important finding of our review is that when disutilities are based on
assumption, investigators tend to overestimate the harms; these methodological risks should
be considered in cost-effectiveness analyses of cancer screening interventions.
Another important outcome of our review is application a novel framework to assess qual-
ity of studies reporting utility values. Quality of studies on HSUVs in cancer realm is rarely
evaluated and so methodological improvements on this regard are important. One of the few
evaluable estimates is a systematic review of Carter et al (2015), who qualitatively evaluated the
quality of upper digestive tract cancer studies. [66] In our review, about 70% of studies on five
cancers were ranked as medium / high quality. Meanwhile, the studies had important limita-
tion in reporting uncertainty in their findings with only two of them including confidence
intervals. For seven studies it was possible to derive the confidence intervals based on the data
Fig 7. Abnormal result related disutility values in diagnostic work up phase.Notes: 1) abnormal result includes borderline
or mildly dyskaryotic (BMD), cervical dysplasia, atypical squamous cells of undetermined significance (ASCUS), low-graded
squamous intraepithelial lesion (LSIL), high—graded squamous intraepithelial lesion (HSIL), cervical intraepithelial neoplasia
(CIN), Human papillomavirus positive 2) Green color = high quality; Yellow color = medium quality; Grey color = low quality;
Dark color = very low quality 3) with � values from experts; without � form general population.
https://doi.org/10.1371/journal.pone.0220148.g007
Table 3. Summary on measured disutility studies by typology and cancer types.
Studies Number Screening Phase Diagnostic work up Phase Treatment Phase
False Positive Procedure wise Disutility Abnormal result related Disutility Overtreatment
Colorectal cancer 1 2
Cervical Cancer 2 6 7
Breast Cancer 3 5 3
Lung Cancer
Prostate Cancer 3 2 1
https://doi.org/10.1371/journal.pone.0220148.t003
Disutility in cancer screening programs
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reported. While this information did not change the conclusions of the review, it undervalues
even more the importance of disutilities in screening and diagnostic work up phase, with nega-
tive confidence intervals received in three high and medium quality studies.
An interesting observation, is that the higher quality the studies was rated, the lower disutil-
ity values were reported.
Methodological considerations on disutility measurement
Variations in utility elicitation are strongly associated with the instruments used in the study.
[15, 19, 67] We found that the indirect methods tended to retrieve lower disutility value than
the direct methods, in most cases showing no at all. The published literature reported that util-
ity values were generally higher with TTO than with SG, and generally lower with VAS/Rating
Scale (RS). [68–70] In our review due to limited values retrieved, the head-to-head comparison
among TTO, SG and VAS was not feasible. Meanwhile, we observed a trend of higher disutility
values from TTO than VAS/RS. Considering stated, synthesis and interpretation of disutilities
related to cancer screening programs should take into consideration the evaluation instru-
ments used and other methodological differences among the studies. With regard to the DCE,
because of the methodological differences, we could not compare the retrieved disutility values
with other evaluation approaches. Despite a few disadvantages (potential underlying mismatch
with random utility theory, irrational respond issue and difficulty of incorporating QALYs val-
ues), DCE has multiple benefits such as a trade-off between options, less cognitive burden, eas-
ier administration, and less measurement error.[16, 71] Stolk et al (2010) proposed a hybrid of
TTO and DCE, [72] which could maximize the advantages of both methods enabling the preci-
sion utility elicitation. We believe this might be a promising strategy to follow in future studies
assessing disutility of cancer screening programs.
Table 4. Overview of the estimated disutility values.
Typology/Cancer
type
Range of measured disutility values by
instrument
Range of estimated
disutility values
If estimation is within the range of measured
disutility value (Yes or No)
Reference
Screening phase
colorectal cancer NA 0.5–1.0 NA [51–53]
cervical cancer 0–0.02 0.006 Yes [54,55]
breast cancer 0.006–0.2 0–0.75 No [56,57]
Diagnostic work up
phase
a) False positive
result
cervical cancer NA 0.005–0.04 NA [54, 55,58]
breast cancer 0–0.26 0.75 No [57]
lung cancer NA 0.02–0.6 NA [59,60]
b) Procedure wise
breast cancer 0–0.45 0.158 Yes [56]
lung cancer NA 0.1–0.5 NA [60]
c) Abnormal result
cervical cancer (CIN
only)
0.01–0.40 0.03–0.12 Yes [54,55,58,61]
Treatment phase
colorectal cancer NA 0.05–0.70 NA [51, 59]
Notes: NA = not available CIN = cervical intraepithelial neoplasia
https://doi.org/10.1371/journal.pone.0220148.t004
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Impact of the research findings
Our findings suggest that disutilities related to cancer screening are mainly related to diagnos-
tic work up though these results are uncertain because of either not reported or wide confi-
dence intervals. The disutilities related to treatment phase are not explored. While on
population scale the screening phase is the most important for disutilities assessment, since it
affects each screened individual, all high quality studies report zero disutility on this stage
(four studies report zero and one includes zero into the range of values). If high quality studies
are used as a reference point, economic evaluations reporting estimated disutilities relevant to
screening stage overestimate their values. This will lead to overestimation in cost-effectiveness
ratio of cancer screening programs. Besides, when applying probabilistic sensitivity analyses
where utilities and disutilities are assumed to be independent, this assumption will increase
the uncertainty regarding incremental cost-effectiveness estimates.
Limitations
This review is subject to several limitations. First of all, the applied quality criteria need further
validation on the other studies. In addition, given very limited data retrieved per each typology
and heterogeneity of the results, meta-synthesis was not feasible. [73] Considering incompara-
bility between DCE and other direct or indirect methods, we could not incorporate these val-
ues into qualitative synthesis. Lastly, our inclusion criteria were limited to English-language
articles only, which may not identify all the relevant studies.
Research gap
To conclude, further research is needed in the area of disutility assessment. From all the typol-
ogies, the priority should be targeted at the potential moderate level of harms (false-positive
diagnosis and overtreatment). More studies are necessary to assess disutility related to colorec-
tal, lung and prostate cancer screening.
Furthermore, our review identified that around 60% of authors estimated the time frame
for certain health state in their utility studies; therefore, we call for the urgent needs to stan-
dardize the time frame reporting. Lastly, given the advantage of allowing trade-off between
options of DCE method, we think it is valuable to introduce more DCE studies in cancer
screening programs. Such approach will help to improve the evidence for cost utility analysis
and to facilitate further the sound decision making process for cancer screening programs.
Conclusion
Cancer screening programs lead to low disutities related to screening phase, and low to moder-
ate disutilities related to diagnostic work up and treatment phases. These disutility values var-
ied by the measurement instrument applied and study quality.
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